Enterprise Value
1.042B
Cash
234.3M
Avg Qtr Burn
-32.08M
Short % of Float
20.79%
Insider Ownership
21.62%
Institutional Own.
83.80%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INBRX-101 (AAT-Fc fusion protein) Details Genetic disorder, Severe alpha-1 antitrypsin deficiency, Rare genetic disease | Phase 2 Data readout | |
INBRX-109 (DR5 agonist) Details Solid tumor/s, Cancer | Phase 2 Update | |
INBRX-106 (OX40 agonist) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
INBRX-105 (PDL1 X 4-1BB tetravalent conditional agonist) Details Solid tumor/s, Cancer | Phase 1 Data readout |